韩国SARS-CoV-2疫苗接种导致的淋巴腺病的风险:一个自我控制的病例系列分析
Mi-Sook Kim1, Bongyoung Kim2, Jeong Pil Choi3
1Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Korea.
Epidemiology and health
|October 19, 2023
概括
严重急性呼吸道综合征冠状病毒2 (SARS-CoV-2) 疫苗接种,特别是mRNA疫苗,与淋巴腺病的风险更高有关. 这种增加的风险在接种疫苗后不久是最明显的,并且随着时间的推移而减少.
科学领域:
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
- 公共卫生 公共卫生
背景情况:
- 严重急性呼吸系统综合征冠状病毒2 (SARS-CoV-2) 疫苗已在全球范围内广泛使用.
- 淋巴腺病,或淋巴结胀,是众所周知的各种疫苗的潜在副作用.
研究的目的:
- 评估SARS-CoV-2疫苗接种与发展淋巴腺病的风险之间的关联.
- 为了量化COVID-19疫苗接种后期淋巴腺病的风险.
主要方法:
- 采用自我控制的病例系列设计,将接种疫苗后的淋巴腺病风险与基线时期进行比较.
- 亚组分析检查了基于年龄,并发症,疫苗类型和接种疫苗以来的时间的风险变化.
主要成果:
- 在SARS-CoV-2疫苗接种后观察到淋巴腺病风险的统计显著增加 (相对发生率[RI] 1.17).
- 在接种疫苗后的第一段时间 (1-7天) 风险最高,随后降低.
- mRNA疫苗 (mRNA-1273和BNT162b2) 与风险增加有关,特别是在年轻人和伴随疾病较少的人群中.
结论:
- 在统计学上,SARS-CoV-2疫苗接种与淋巴腺病的风险增加有关.
- 这种增加的风险似乎是特定于mRNA疫苗类型.
相关概念视频
Single Nucleotide Polymorphisms-SNPs
15.2K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.2K
Factors Affecting the Risk of Infection
11.9K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.9K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Relative Risk
191
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
191
Vaccinations
44.6K
Overview
44.6K
Cancer Vaccines
383
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
383


